Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dombernowsky, P.
Right arrow Articles by Trunet, P. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dombernowsky, P.
Right arrow Articles by Trunet, P. F.

Journal of Clinical Oncology, Vol 16, 453-461, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

P Dombernowsky, I Smith, G Falkson, R Leonard, L Panasci, J Bellmunt, W Bezwoda, G Gardin, A Gudgeon, M Morgan, A Fornasiero, W Hoffmann, J Michel, T Hatschek, T Tjabbes, HA Chaudri, U Hornberger and PF Trunet

PURPOSE: To compare two doses of letrozole and megestrol acetate (MA) as second-line therapy in postmenopausal women with advanced breast cancer previously treated with antiestrogens. PATIENTS AND METHODS: Five hundred fifty-one patients with locally advanced, locoregionally recurrent or metastatic breast cancer were randomly assigned to receive letrozole 2.5 mg (n = 174), letrozole 0.5 mg (n = 188), or MA 160 mg (n = 189) once daily in a double-blind, multicenter trial. Data were analyzed for tumor response and safety variables up to 33 months of follow-up evaluation and for survival up to 45 months. RESULTS: Letrozole 2.5 mg produced a significantly higher overall objective response rate (24%) compared with MA (16%; logistic regression, P = .04) or letrozole 0.5 mg (13%; P = .004). Duration of objective response was significantly longer for letrozole 2.5 mg compared with MA (Cox regression, P = .02). Letrozole 2.5 mg was significantly superior to MA and letrozole 0.5 mg in time to treatment failure (P = .04 and P = .002, respectively). For time to progression, letrozole 2.5 mg was superior to letrozole 0.5 mg (P = .02), but not to MA (P = .07). There was a significant dose effect in overall survival in favor of letrozole 2.5 mg (P = .03) compared with letrozole 0.5 mg. Letrozole was significantly better tolerated than MA with respect to serious adverse experiences, discontinuation due to poor tolerability, cardiovascular side effects, and weight gain. CONCLUSION: The data show letrozole 2.5 mg once daily to be more effective and better tolerated than MA in the treatment of postmenopausal women with advanced breast cancer previously treated with antiestrogens.


This article has been cited by other articles:


Home page
 Journal of Pharmacy PracticeHome page
R. E. Greene and V. Tsang
Hormonal Therapy for the Treatment of Postmenopausal Breast Cancer Patients
Journal of Pharmacy Practice, February 1, 2008; 21(1): 36 - 45.
[Abstract] [PDF]

Home page
 The OncologistHome page
M. Colozza, E. de Azambuja, N. Personeni, F. Lebrun, M. J. Piccart, and F. Cardoso
Achievements in Systemic Therapies in the Pregenomic Era in Metastatic Breast Cancer
Oncologist, March 1, 2007; 12(3): 253 - 270.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S Beslija, J Bonneterre, H Burstein, V Cocquyt, M Gnant, P Goodwin, V Heinemann, J Jassem, W. Kostler, M Krainer, et al.
Second consensus on medical treatment of metastatic breast cancer
Ann. Onc., February 1, 2007; 18(2): 215 - 225.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
D. Mauri, N. Pavlidis, N. P. Polyzos, and J. P. A. Ioannidis
Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
J Natl Cancer Inst, September 20, 2006; 98(18): 1285 - 1291.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. J. Pietras
Biologic Basis of Sequential and Combination Therapies for Hormone-Responsive Breast Cancer
Oncologist, July 1, 2006; 11(7): 704 - 717.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
K. Altundag and N. K. Ibrahim
Aromatase inhibitors in breast cancer: an overview.
Oncologist, June 1, 2006; 11(6): 553 - 562.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Neyt, J. Albrecht, and V. Cocquyt
An economic evaluation of Herceptin(R) in adjuvant setting: the Breast Cancer International Research Group 006 trial
Ann. Onc., March 1, 2006; 17(3): 381 - 390.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
I. Vergote and P. Abram
Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents
Ann. Onc., February 1, 2006; 17(2): 200 - 204.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
N. Normanno, M. Di Maio, E. De Maio, A. De Luca, A. de Matteis, A. Giordano, F. Perrone, and on behalf of the NCI-Naples Breast Cancer Group
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer
Endocr. Relat. Cancer, December 1, 2005; 12(4): 721 - 747.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
L-A Martin, S Pancholi, C M W Chan, I Farmer, C Kimberley, M Dowsett, and S R D Johnston
The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling
Endocr. Relat. Cancer, December 1, 2005; 12(4): 1017 - 1036.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
H. Gogas, C. Markopoulos, and R. Blamey
Should women be advised to take prophylactic endocrine treatment outside of a clinical trial setting?
Ann. Onc., December 1, 2005; 16(12): 1861 - 1866.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. J. Whelan, P. E. Goss, J. N. Ingle, J. L. Pater, D. Tu, K. Pritchard, S. Liu, L. E. Shepherd, M. Palmer, N. J. Robert, et al.
Assessment of Quality of Life in MA.17: A Randomized, Placebo-Controlled Trial of Letrozole After 5 Years of Tamoxifen in Postmenopausal Women
J. Clin. Oncol., October 1, 2005; 23(28): 6931 - 6940.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Boulay, J. Rudloff, J. Ye, S. Zumstein-Mecker, T. O'Reilly, D. B. Evans, S. Chen, and H. A. Lane
Dual Inhibition of mTOR and Estrogen Receptor Signaling In vitro Induces Cell Death in Models of Breast Cancer
Clin. Cancer Res., July 15, 2005; 11(14): 5319 - 5328.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
A. Howell and A. M Wardley
Overview of the impact of conventional systemic therapies on breast cancer
Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S9 - S16.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
R. W. Brueggemeier, J. C. Hackett, and E. S. Diaz-Cruz
Aromatase Inhibitors in the Treatment of Breast Cancer
Endocr. Rev., May 1, 2005; 26(3): 331 - 345.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
R. Kudachadkar and R. M. O'Regan
Aromatase Inhibitors as Adjuvant Therapy for Postmenopausal Patients With Early Stage Breast Cancer
CA Cancer J Clin, May 1, 2005; 55(3): 145 - 163.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Cuzick
Aromatase Inhibitors for Breast Cancer Prevention
J. Clin. Oncol., March 10, 2005; 23(8): 1636 - 1643.
[Full Text] [PDF]

Home page
 JCOHome page
K. Strasser-Weippl and P. E. Goss
Advances in Adjuvant Hormonal Therapy for Postmenopausal Women
J. Clin. Oncol., March 10, 2005; 23(8): 1751 - 1759.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. R. Love, P. R. Hutson, T. C. Havighurst, and J. F. Cleary
Endocrine Effects of Tamoxifen Plus Exemestane in Postmenopausal Women with Breast Cancer
Clin. Cancer Res., February 15, 2005; 11(4): 1500 - 1503.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. S. Tobias
Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention
Ann. Onc., December 1, 2004; 15(12): 1738 - 1747.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. Bernard-Marty, F. Cardoso, and M. J. Piccart
Facts and Controversies in Systemic Treatment of Metastatic Breast Cancer
Oncologist, November 1, 2004; 9(6): 617 - 632.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
N Angelopoulos, V Barbounis, S Livadas, D Kaltsas, and G Tolis
Effects of estrogen deprivation due to breast cancer treatment
Endocr. Relat. Cancer, September 1, 2004; 11(3): 523 - 535.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
H. Mouridsen, Y. Sun, M. Gershanovich, R. Perez-Carrion, D. Becquart, H.A. Chaudri-Ross, and R. Lang
Superiority of Letrozole to Tamoxifen in the First-Line Treatment of Advanced Breast Cancer: Evidence from Metastatic Subgroups and a Test of Functional Ability
Oncologist, September 1, 2004; 9(5): 489 - 496.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Andre, K. Slimane, T. Bachelot, A. Dunant, M. Namer, A. Barrelier, O. Kabbaj, J. P. Spano, H. Marsiglia, R. Rouzier, et al.
Breast Cancer With Synchronous Metastases: Trends in Survival During a 14-Year Period
J. Clin. Oncol., August 15, 2004; 22(16): 3302 - 3308.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
W. J. Gradishar
Tamoxifen--What Next?
Oncologist, July 1, 2004; 9(4): 378 - 384.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Ellis
Overcoming Endocrine Therapy Resistance by Signal Transduction Inhibition
Oncologist, June 3, 2004; 9(suppl_3): 20 - 26.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. M. Campos
Aromatase Inhibitors for Breast Cancer in Postmenopausal Women
Oncologist, April 1, 2004; 9(2): 126 - 136.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
B. J. Long, D. Jelovac, V. Handratta, A. Thiantanawat, N. MacPherson, J. Ragaz, O. G. Goloubeva, and A. M. Brodie
Therapeutic Strategies Using the Aromatase Inhibitor Letrozole and Tamoxifen in a Breast Cancer Model
J Natl Cancer Inst, March 17, 2004; 96(6): 456 - 465.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
R. C. Coombes, E. Hall, L. J. Gibson, R. Paridaens, J. Jassem, T. Delozier, S. E. Jones, I. Alvarez, G. Bertelli, O. Ortmann, et al.
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
N. Engl. J. Med., March 11, 2004; 350(11): 1081 - 1092.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. U. Buzdar
Data from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trial: Implications for Use of Aromatase Inhibitors in 2003
Clin. Cancer Res., January 1, 2004; 10(1): 355S - 361S.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. N. Ingle
Sequencing of Endocrine Therapy in Postmenopausal Women with Advanced Breast Cancer
Clin. Cancer Res., January 1, 2004; 10(1): 362S - 367S.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. J. Ellis, A. Coop, B. Singh, Y. Tao, A. Llombart-Cussac, F. Janicke, L. Mauriac, E. Quebe-Fehling, H. A. Chaudri-Ross, D. B. Evans, et al.
Letrozole Inhibits Tumor Proliferation More Effectively than Tamoxifen Independent of HER1/2 Expression Status
Cancer Res., October 1, 2003; 63(19): 6523 - 6531.
[Abstract] [Full Text] [PDF]

Home page
 Clin Med ResHome page
E. P. Mamounas
NSABP Breast Cancer Clinical Trials: Recent Results and Future Directions
Clin. Med. Res., October 1, 2003; 1(4): 309 - 326.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. Paridaens, L. Dirix, C. Lohrisch, L. Beex, M. Nooij, D. Cameron, L. Biganzoli, T. Cufer, L. Duchateau, A. Hamilton, et al.
Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer
Ann. Onc., September 1, 2003; 14(9): 1391 - 1398.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Waeber, M. Castiglione-Gertsch, D. Dietrich, B. Thurlimann, A. Goldhirsch, K. W. Brunner, and M. M. Borner
Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation
Ann. Onc., August 1, 2003; 14(8): 1215 - 1221.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. U. Buzdar
Advances in Endocrine Treatments for Postmenopausal Women with Metastatic and Early Breast Cancer
Oncologist, August 1, 2003; 8(4): 335 - 341.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Piccart, L. M. Parker, and K. I. Pritchard
Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer
Ann. Onc., July 1, 2003; 14(7): 1017 - 1025.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
I. E. Smith and M. Dowsett
Aromatase Inhibitors in Breast Cancer
N. Engl. J. Med., June 12, 2003; 348(24): 2431 - 2442.
[Full Text] [PDF]

Home page
 JCOHome page
H. Mouridsen, M. Gershanovich, Y. Sun, R. Perez-Carrion, C. Boni, A. Monnier, J. Apffelstaedt, R. Smith, H. P. Sleeboom, F. Jaenicke, et al.
Phase III Study of Letrozole Versus Tamoxifen as First-Line Therapy of Advanced Breast Cancer in Postmenopausal Women: Analysis of Survival and Update of Efficacy From the International Letrozole Breast Cancer Group
J. Clin. Oncol., June 1, 2003; 21(11): 2101 - 2109.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
V. Valero and G. N. Hortobagyi
Are Anthracycline-Taxane Regimens the New Standard of Care in the Treatment of Metastatic Breast Cancer?
J. Clin. Oncol., March 15, 2003; 21(6): 959 - 962.
[Full Text] [PDF]

Home page
 JCOHome page
F. J. Esteva, J. Glaspy, S. Baidas, L. Laufman, L. Hutchins, M. Dickler, D. Tripathy, R. Cohen, A. DeMichele, R. C. Yocum, et al.
Multicenter Phase II Study of Oral Bexarotene for Patients With Metastatic Breast Cancer
J. Clin. Oncol., March 15, 2003; 21(6): 999 - 1006.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
T. Tominaga, I. Adachi, Y. Sasaki, T. Tabei, T. Ikeda, Y. Takatsuka, M. Toi, T. Suwa, and Y. Ohashi
Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer
Ann. Onc., January 1, 2003; 14(1): 62 - 70.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. I. Pritchard
Endocrine Therapy of Advanced Disease: Analysis and Implications of the Existing Data
Clin. Cancer Res., January 1, 2003; 9(1): 460S - 467S.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. U. Buzdar
Pharmacology and Pharmacokinetics of the Newer Generation Aromatase Inhibitors
Clin. Cancer Res., January 1, 2003; 9(1): 468S - 472S.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. A. Ligibel and E. P. Winer
Clinical Differences among the Aromatase Inhibitors
Clin. Cancer Res., January 1, 2003; 9(1): 473S - 479S.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
I. C. Henderson
A Rose Is No Longer a Rose
J. Clin. Oncol., August 15, 2002; 20(16): 3365 - 3368.
[Full Text] [PDF]

Home page
 JCOHome page
E. P. Winer, C. Hudis, H. J. Burstein, R. T. Chlebowski, J. N. Ingle, S. B. Edge, E. P. Mamounas, J. Gralow, L. J. Goldstein, K. I. Pritchard, et al.
American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Women With Hormone Receptor-Positive Breast Cancer: Status Report 2002
J. Clin. Oncol., August 1, 2002; 20(15): 3317 - 3327.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E. Bajetta, A. Martinetti, N. Zilembo, P. Pozzi, I. La Torre, L. Ferrari, E. Seregni, R. Longarini, G. Salvucci, and E. Bombardieri
Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism
Ann. Onc., July 1, 2002; 13(7): 1059 - 1066.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. J. Long, D. Jelovac, A. Thiantanawat, and A. M. Brodie
The Effect of Second-Line Antiestrogen Therapy on Breast Tumor Growth after First-Line Treatment with the Aromatase Inhibitor Letrozole: Long-Term Studies Using the Intratumoral Aromatase Postmenopausal Breast Cancer Model
Clin. Cancer Res., July 1, 2002; 8(7): 2378 - 2388.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. H. Cohen, J. R. Johnson, N. Li, G. Chen, and R. Pazdur
Approval Summary: Letrozole in the Treatment of Postmenopausal Women with Advanced Breast Cancer
Clin. Cancer Res., March 1, 2002; 8(3): 665 - 669.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
R. M. O'Regan, C. Gajdos, R. C. Dardes, A. De Los Reyes, W. Park, A. W. Rademaker, and V. C. Jordan
Effects of Raloxifene After Tamoxifen on Breast and Endometrial Tumor Growth in Athymic Mice
J Natl Cancer Inst, February 20, 2002; 94(4): 274 - 283.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Geisler, B. Haynes, G. Anker, M. Dowsett, and P. E. Lonning
Influence of Letrozole and Anastrozole on Total Body Aromatization and Plasma Estrogen Levels in Postmenopausal Breast Cancer Patients Evaluated in a Randomized, Cross-Over Study
J. Clin. Oncol., February 1, 2002; 20(3): 751 - 757.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. U. Buzdar, H. Mouridsen, and H. A. Chaudri-Ross
Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy
J. Clin. Oncol., February 1, 2002; 20(3): 876 - 878.
[Full Text] [PDF]

Home page
 Recent Prog Horm ResHome page
E. R. Simpson and M. Dowsett
Aromatase and Its Inhibitors: Significance for Breast Cancer Therapy
Recent Prog. Horm. Res., January 1, 2002; 57(1): 317 - 338.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Cocconi
False Shortening of Time to Progression in Letrozole 2.5-mg Dose?
J. Clin. Oncol., December 1, 2001; 19(23): 4353 - 4353.
[Full Text]

Home page
 JCOHome page
J. R. Mackey, A. A. Joy, A. U. Buzdar, C. Brady, and H. A. Chaudri-Ross
Letrozole in Second-Line Therapy of Advanced Breast Cancer: More Questions Than Answers
J. Clin. Oncol., December 1, 2001; 19(23): 4353 - 4355.
[Full Text]

Home page
 JCOHome page